Syndax Pharmaceuticals filed an 8-K reporting financial results and corporate presentation for the quarter and six months ended September 30, 2025. CEO Michael A. Metzger certified the filing.
Financial Performance (3Q25): Total revenue reached \(45.9 million, a 21% sequential increase. Revuforj net revenue was \)32.0 million (up 12% Q/Q). Collaboration revenue from Niktimvo contributed \(13.9 million (up 25% Q/Q for the share). The net loss narrowed significantly to \)60.7 million (\(0.70 per share diluted), an improvement from \)84.1 million in 3Q24. The cash position remains strong at $456.1
...